English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/114335
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Receptor-Based Virtual Screening and Biological Characterization of Human Apurinic/Apyrimidinic Endonuclease (Ape1) Inhibitors

AuthorsRuiz, Federico M. ; Francis, Sandrea M. ; Tintoré, María ; Ferreira, Rubén ; Gil Redondo, Rubén ; Morreale, Antonio ; Ortiz, Ángel R. ; Eritja Casadellà, Ramón ; Fràbrega, Carmen
Issue DateDec-2012
PublisherWiley-VCH
CitationChemMedChem 7(12): 2168-2178 (2012)
AbstractThe endonucleolytic activity of human apurinic/apyrimidinic endonuclease (AP endo, Ape1) is a major factor in maintaining the integrity of the genome. Conversely, as an undesired effect, Ape1 overexpression has been linked to resistance to radio- and chemotherapeutic treatments in several human tumors. Inhibition of Ape1 using siRNA or the expression of a dominant negative form of the protein has been shown to sensitize cells to DNA-damaging agents, including various chemotherapeutic agents. Therefore, inhibition of the enzymatic activity of Ape1 might result in a potent antitumor therapy. A number of small molecules have been described as Ape1 inhibitors; however, those compounds are in the early stages of development. Herein we report the identification of new compounds as potential Ape1 inhibitors through a docking-based virtual screening technique. Some of the compounds identified have invitro activities in the low-to-medium micromolar range. Interaction of these compounds with the Ape1 protein was observed by mass spectrometry. These molecules also potentiate the cytotoxicity of the chemotherapeutic agent methyl methanesulfonate in fibrosarcoma cells. This study demonstrates the power of docking and virtual screening techniques as initial steps in the design of new drugs, and opens the door to the development of a new generation of Ape1 inhibitors.
Publisher version (URL)http://doi.org/10.1002/cmdc.201200372
URIhttp://hdl.handle.net/10261/114335
DOI10.1002/cmdc.201200372
Identifiersissn: 1860-7179
Appears in Collections:(CIB) Artículos
(CBM) Artículos
Files in This Item:
File Description SizeFormat 
Ruiz2012ChemMedChem_APE1.pdf455,8 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.